Liu Wei, Wan Qiu, Zhou Enzhu, He Ping, Tang Lixin
Department of Emergency Eedicine, Chongqing Public Health Medical Center, Shapingba 400000, Chongqing, China.
Department of Respiratory Geriatrics, Chongqing Public Health Medical Center, Shapingba 400000, Chongqing, China.
J Oncol. 2023 Jan 27;2023:3965198. doi: 10.1155/2023/3965198. eCollection 2023.
Due to the absence of accurate tools for early detection and successful treatment, lung adenocarcinoma (LUAD) is one of the most aggressive tumors with high morbidity and mortality globally. It is absolutely necessary to investigate the process behind its development and search for new biomarkers that could aid in the early detection of LUAD. There is a correlation between the immune microenvironment of the tumor and the prognosis of lung cancer as well as the efficacy of immunotherapy. Long noncoding RNAs (lncRNAs) have been identified as potential prognostic biomarkers linked to immunological activities. In this study, we identified 1 downregulated lncRNA and 76 upregulated lncRNAs in LUAD samples from TCGA datasets. Among the 77 dysregulated lncRNAs, our attention focused on lncRNA LINC01833 (LINC01833). When compared with nontumor specimens, the level of expression of LINC01833 was shown to be significantly elevated in LUAD samples. In addition, the data of the ROC study revealed that LUAD patients with high LINC01833 expression had an AUC value of 0.840 (95% confidence interval: 0.804 to 0.876). There was a correlation between high LINC01833 expression and an advanced clinical stage. Patients who had a high expression of LINC01833 were shown to have a lower overall survival rate ( < 0.001) and a lower disease-specific survival rate ( = 0.004) in comparison to patients who were in the low LINC01833 group, according to the data on survival. In addition, the results of the multivariate analysis revealed that high LINC01833 expression was an independent predictor of poor survival in LUAD. Moreover, the immune analysis revealed that we found that the expression of LINC01833 was positively associated with Th2 cells, aDC, and Tgd, while negatively associated with Mast cells, Tcm, Eosinophils, iDC, DC, Tem, Th17 cells, and pDC. Overall, our data point to the possibility that the unique lncRNA LINC01833 might be employed as a diagnostic and prognostic marker, and as a result, it has a significant impact on clinical practice.
由于缺乏早期检测和成功治疗的准确工具，肺腺癌（LUAD）是全球发病率和死亡率最高的侵袭性肿瘤之一。研究其发展背后的过程并寻找有助于LUAD早期检测的新生物标志物是绝对必要的。肿瘤免疫微环境与肺癌预后以及免疫治疗疗效之间存在关联。长链非编码RNA（lncRNAs）已被确定为与免疫活动相关的潜在预后生物标志物。在本研究中，我们从TCGA数据集中鉴定出LUAD样本中有1个lncRNA下调，76个lncRNA上调。在这77个失调的lncRNA中，我们将注意力集中在lncRNA LINC01833（LINC01833）上。与非肿瘤标本相比，LINC01833在LUAD样本中的表达水平显著升高。此外，ROC研究数据显示，LINC01833高表达的LUAD患者的AUC值为0.840（95%置信区间：0.804至0.876）。LINC01833高表达与临床晚期相关。根据生存数据，与LINC01833低表达组的患者相比，LINC01833高表达的患者总生存率较低（<0.001），疾病特异性生存率较低（=0.004）。此外，多变量分析结果显示，LINC01833高表达是LUAD患者生存不良的独立预测因子。此外，免疫分析表明，我们发现LINC01833的表达与Th2细胞、aDC和Tgd呈正相关，而与肥大细胞、Tcm、嗜酸性粒细胞、iDC、DC、Tem、Th17细胞和pDC呈负相关。总体而言，我们的数据表明，独特的lncRNA LINC01833可能用作诊断和预后标志物，因此，它对临床实践具有重大影响。
